Press release content from Globe Newswire. The AP news staff was not involved in its creation.
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II .
InflaRx N.V.May 11, 2021 GMT
U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of care
EU IXCHANGE Phase II trial is fully enrolled with results expected by the end of 2021
JENA, Germany, May 11, 2021 (GLOBE NEWSWIRE) InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today positive topline results from its U.S. Phase II IXPLORE study with vilobelimab in patients with anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis, or AAV.